Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line Tocilizumab in Active Takayasu Arteritis
NCT02101333Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2014
- Primary completion
- Dec 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in Takayasu arteritis (TAK), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT02101333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101333.